Tirzepatide Phase 1 PK Study in Japanese Patients
A Phase 1 MAD study in Japanese T2D patients revealed tirzepatide's ~5-day half-life, dose-dependent glucose reductions, and tolerability profile.
A Phase 1 MAD study in Japanese T2D patients revealed tirzepatide's ~5-day half-life, dose-dependent glucose reductions, and tolerability profile.